GPCRdb

Ligand source activities (1 row/activity)

Potency
Affinity

Get vendors

Ligands					Receptor			Assay information							Chemical information
Sel. page	Common name	GPCRdb ID	#Vendors	Reference ligand	Fold selectivity (Potency)	# tested GPCRs (Potency)	Species	p-value (-log)	Type	Activity Relation	Activity Value	Assay Type	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
	CHEMBL3102930	209292	0	None	-	1	Human	10.3	pEC50	=	10.3	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	168299476	192144	0	None	-1	3	Human	10.2	pEC50	=	10.2	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL5220770	192144	0	None	-1	3	Human	10.2	pEC50	=	10.2	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL4294827	211784	0	None	2	2	Human	10.1	pEC50	=	10.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NC(CC(N)=O)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O	nan
	CHEMBL1893324	207316	20	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O	10.1021/acs.jmedchem.0c01396
	2263	255	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	44566111	255	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL219499	255	0	None	-1	3	Human	10.1	pEC50	=	10.1	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL3102924	209286	0	None	-	1	Human	10.0	pEC50	=	10	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102925	209287	0	None	-	1	Human	10.0	pEC50	=	10.0	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL3102919	209281	0	None	-	1	Human	9.9	pEC50	=	9.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277441	211623	0	None	1202	2	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	1152	3932	13	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	16129679	3932	13	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	53395115	3932	13	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	91898389	3932	13	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL1981592	3932	13	None	-3	8	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102922	209284	0	None	-	1	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102929	209291	0	None	-	1	Human	9.7	pEC50	=	9.7	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102931	209293	0	None	-	1	Human	9.5	pEC50	=	9.5	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102921	209283	0	None	-	1	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3105020	209325	0	None	-	1	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4291119	211758	0	None	22	2	Human	9.4	pEC50	=	9.4	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCCN)CC(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277799	211632	0	None	977	2	Human	9.3	pEC50	=	9.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4285873	211711	0	None	-	1	Human	9.2	pEC50	=	9.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL440082	212112	0	None	-	1	Human	9.2	pEC50	=	9.2	Functional	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
	CHEMBL4282016	211680	0	None	204	2	Human	9.2	pEC50	=	9.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281547	211673	0	None	-	1	Human	9.1	pEC50	=	9.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277870	211633	0	None	1659	2	Human	9.1	pEC50	=	9.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4294951	211786	0	None	-	1	Human	9.0	pEC50	=	9.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4289726	211739	0	None	-	1	Human	9.0	pEC50	=	9.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL3102923	209285	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL4291903	211763	0	None	660	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL4276843	211619	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4286419	211715	0	None	234	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4282364	211683	0	None	1071	2	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NC(CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102926	209288	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL4283432	211692	0	None	-	1	Human	8.9	pEC50	=	8.9	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCNC(=N)N)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102927	209289	0	None	-	1	Human	8.8	pEC50	=	8.8	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL3105019	209324	0	None	-	1	Human	8.8	pEC50	=	8.8	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4294843	211785	0	None	-11	2	Human	7.0	pEC50	=	7.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)NC(CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4281814	211676	0	None	-58	2	Human	6.6	pEC50	=	6.6	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284858	211701	0	None	-	1	Human	8.5	pEC50	=	8.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4287451	211721	0	None	426	2	Human	8.5	pEC50	=	8.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NC(CCC(N)=O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102928	209290	0	None	-	1	Human	8.4	pEC50	=	8.4	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC	10.1021/ml400257h
	CHEMBL4280273	211657	0	None	-	1	Human	6.5	pEC50	=	6.5	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4277709	211629	0	None	-870	2	Human	5.3	pEC50	=	5.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4278228	211640	0	None	-	1	Human	8.3	pEC50	=	8.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281905	211678	0	None	1	2	Human	7.3	pEC50	=	7.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4285866	211710	0	None	-	1	Human	6.3	pEC50	=	6.3	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL3102920	209282	0	None	-	1	Human	8.2	pEC50	=	8.2	Functional	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277783	211631	0	None	1	2	Human	6.2	pEC50	=	6.2	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CC(CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284839	211700	0	None	-11	2	Human	6.1	pEC50	=	6.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4280734	211661	0	None	-223	2	Human	7.1	pEC50	=	7.1	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284961	211703	0	None	9	2	Human	7.0	pEC50	=	7.0	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CC(Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O	nan
	CHEMBL4278811	211644	0	None	-	1	Human	6.0	pEC50	=	6	Functional	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	11570626	2513	40	None	-794	9	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	9135	2513	40	None	-794	9	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	CHEMBL1933349	2513	40	None	-794	9	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	DB12044	2513	40	None	-794	9	Human	4.9	pIC50	=	4.9	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	60170971	80989	0	None	-186	3	Human	5.8	pIC50	=	5.8	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159348	80989	0	None	-186	3	Human	5.8	pIC50	=	5.8	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60170970	80988	0	None	-281	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159347	80988	0	None	-281	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60171059	80990	0	None	-794	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159349	80990	0	None	-794	4	Human	5.6	pIC50	=	5.6	Functional	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	90154832	152585	0	None	-	1	Human	5.4	pIC50	=	5.4	Functional	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	152585	0	None	-	1	Human	5.4	pIC50	=	5.4	Functional	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	168298339	192107	0	None	-1	3	Human	8.4	pIC50	=	8.4	Functional	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	CHEMBL5219662	192107	0	None	-1	3	Human	8.4	pIC50	=	8.4	Functional	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	1152	3932	13	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3932	13	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3932	13	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3932	13	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3932	13	None	-3	8	Human	7.3	pEC50	=	7.3	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16133238	2941	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2941	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2941	0	None	-85	6	Human	7.6	pEC50	=	7.6	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2942	0	None	-17	4	Human	7.7	pEC50	=	7.7	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	1152	3932	13	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16129679	3932	13	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	53395115	3932	13	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	91898389	3932	13	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	CHEMBL1981592	3932	13	None	-3	8	Human	7.8	pEC50	=	7.8	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2272	3029	0	None	14	3	Human	8.3	pEC50	=	8.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2259	3294	0	None	190	4	Human	8.3	pEC50	=	8.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	1152	3932	13	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3932	13	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3932	13	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3932	13	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3932	13	None	-3	8	Human	9.2	pEC50	=	9.2	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2942	0	None	-17	4	Human	9.3	pEC50	=	9.3	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	129887154	576	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	576	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	576	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	576	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	576	0	None	177	3	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16133238	2941	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2941	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2941	0	None	-85	6	Human	9.4	pEC50	=	9.4	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2272	3029	0	None	14	3	Human	8.4	pEC50	=	8.4	Functional	inhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptorinhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	325	0	None	-4168	3	Human	5.9	pEC50	=	5.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3932	13	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16129679	3932	13	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	53395115	3932	13	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	91898389	3932	13	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	CHEMBL1981592	3932	13	None	-3	8	Human	7.9	pEC50	=	7.9	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16133238	2941	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2257	2941	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	44134520	2941	0	None	-85	6	Human	8.4	pEC50	=	8.4	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2276	3293	0	None	316	2	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	1152	3932	13	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16129679	3932	13	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	53395115	3932	13	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	91898389	3932	13	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	CHEMBL1981592	3932	13	None	-3	8	Human	8.5	pEC50	=	8.5	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3294	0	None	190	4	Human	8.7	pEC50	=	8.7	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	1152	3932	13	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	16129679	3932	13	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	53395115	3932	13	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	91898389	3932	13	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	CHEMBL1981592	3932	13	None	-3	8	Human	9.3	pEC50	=	9.3	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	2278	325	0	None	-4168	3	Human	5.0	pEC50	>	5	Functional	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	325	0	None	-4168	3	Human	5.0	pEC50	>	5	Functional	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	3842	2403	0	None	-1584	5	Human	6.0	pEC50	>	6	Functional	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2272	3029	0	None	14	3	Human	7.6	pIC50	=	7.6	Functional	inhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptorinhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633

Get vendors

Ligands					Receptor			Assay information							Chemical information
Sel. page	Common name	GPCRdb ID	#Vendors	Reference ligand	Fold selectivity (Affinity)	# tested GPCRs (Affinity)	Species	p-value (-log)	Type	Activity Relation	Activity Value	Assay Type	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
	CHEMBL524852	213845	4	None	-	0	Human	8.0	pIC50	=	8.0	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	118334911	143784	0	None	-	0	Human	5.0	pIC50	=	5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
	CHEMBL3905363	143784	0	None	-	0	Human	5.0	pIC50	=	5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
	73890927	148363	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3941654	148363	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334840	147998	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3938565	147998	0	None	-	0	Human	6.0	pIC50	=	6.0	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334843	148720	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3944350	148720	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	2263	255	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	44566111	255	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL219499	255	0	None	-	1	Human	7.9	pIC50	=	7.9	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	90154832	152585	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	152585	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	118334841	152987	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3979900	152987	0	None	-	0	Human	5.9	pIC50	=	5.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334918	148320	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
	CHEMBL3941270	148320	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
	118334912	153788	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3986723	153788	0	None	-	0	Human	4.9	pIC50	=	4.9	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334831	146583	0	None	-	0	Human	6.7	pIC50	=	6.7	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL3927475	146583	0	None	-	0	Human	6.7	pIC50	=	6.7	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL507480	212564	0	None	-	0	Human	7.6	pIC50	=	7.6	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	90154832	152585	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	152585	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	118334842	153318	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
	CHEMBL3982797	153318	0	None	-	0	Human	5.6	pIC50	=	5.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
	CHEMBL440082	212112	0	None	-	0	Human	7.6	pIC50	=	7.6	Binding	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
	118334830	153711	0	None	-	0	Human	6.6	pIC50	=	6.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	CHEMBL3986225	153711	0	None	-	0	Human	6.6	pIC50	=	6.6	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	118334834	151779	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3969613	151779	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	127035881	135962	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736134	135962	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	127035881	135962	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736134	135962	0	None	-	0	Human	7.4	pIC50	=	7.4	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	90154607	153270	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
	CHEMBL3982346	153270	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
	118334924	146604	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	CHEMBL3927669	146604	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	118334910	144115	0	None	-	0	Human	4.4	pIC50	=	4.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3908152	144115	0	None	-	0	Human	4.4	pIC50	=	4.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334914	150827	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3961248	150827	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334919	153001	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3980013	153001	0	None	-	0	Human	5.4	pIC50	=	5.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	73890939	152299	0	None	-	0	Human	6.4	pIC50	=	6.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3973956	152299	0	None	-	0	Human	6.4	pIC50	=	6.4	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334917	150671	0	None	-	0	Human	4.3	pIC50	=	4.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3959870	150671	0	None	-	0	Human	4.3	pIC50	=	4.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334925	141857	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
	CHEMBL3889643	141857	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
	127034614	135980	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736230	135980	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	127034614	135980	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736230	135980	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	118334931	141910	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL3890096	141910	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	118334909	148880	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
	CHEMBL3945729	148880	0	None	-	0	Human	5.2	pIC50	=	5.2	Binding	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
	3842	2403	0	None	-	0	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1155	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129665	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3643	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1201488	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	DB00021	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3293	465	0	None	-	0	Rat	5.0	pIC50	=	5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3293	465	0	None	-	0	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1155	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129665	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3643	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1201488	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	DB00021	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1152	3932	13	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129679	3932	13	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	53395115	3932	13	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	91898389	3932	13	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1981592	3932	13	None	-5	4	Human	8.3	pIC50	=	8.3	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1152	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129679	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	53395115	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	91898389	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1981592	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	129887154	576	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	576	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	576	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	576	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	576	0	None	-	1	Human	7.2	pIC50	=	7.2	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16133238	2941	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2257	2941	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	44134520	2941	0	None	-	3	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	131850923	3028	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	155817437	3028	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	16154651	3028	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2268	3028	0	None	-	0	Human	5.5	pIC50	=	5.5	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	131850923	3028	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	155817437	3028	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	16154651	3028	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2268	3028	0	None	-	0	Rat	5.7	pIC50	=	5.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2266	2850	0	None	-	0	Human	7.3	pIC50	=	7.3	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16133238	2941	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2257	2941	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	44134520	2941	0	None	-	3	Human	7.6	pIC50	=	7.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	1152	3932	13	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16129679	3932	13	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	53395115	3932	13	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	91898389	3932	13	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	CHEMBL1981592	3932	13	None	-5	4	Human	7.7	pIC50	=	7.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3294	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2259	3294	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3294	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9145428
	1155	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129665	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	3643	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1201488	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	DB00021	3516	0	None	-	2	Rat	4.5	pIC50	=	4.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1155	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129665	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	3643	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1201488	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	DB00021	3516	0	None	-	2	Human	5.3	pIC50	=	5.3	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	131850923	3028	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	155817437	3028	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16154651	3028	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2268	3028	0	None	-	0	Human	5.7	pIC50	=	5.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2273	3060	0	None	-	0	Human	7.5	pIC50	=	7.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2273	3060	0	None	-	0	Rat	7.5	pIC50	=	7.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16133238	2941	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16133238	2941	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2257	2941	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2257	2941	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	44134520	2941	0	None	-	3	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	44134520	2941	0	None	-	3	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2275	3064	0	None	-	0	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1152	3932	13	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	1152	3932	13	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	16129679	3932	13	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	16129679	3932	13	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	53395115	3932	13	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	53395115	3932	13	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	91898389	3932	13	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	91898389	3932	13	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	CHEMBL1981592	3932	13	None	-5	4	Human	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	CHEMBL1981592	3932	13	None	-	4	Rat	8.0	pIC50	=	8	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	2275	3064	0	None	-	0	Rat	8.2	pIC50	=	8.2	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1152	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129679	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53395115	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	91898389	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1981592	3932	13	None	-	4	Rat	8.4	pIC50	=	8.4	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16132369	1887	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16132369	1887	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2280	1887	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2280	1887	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53230038	1887	0	None	-	1	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53230038	1887	0	None	-	1	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2271	2851	0	None	-	0	Rat	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	1152	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	1152	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129679	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16129679	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53395115	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	53395115	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	91898389	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	91898389	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1981592	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	CHEMBL1981592	3932	13	None	-5	4	Human	8.5	pIC50	=	8.5	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2272	3029	0	None	-	0	Human	8.7	pIC50	=	8.7	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11068102
	2271	2851	0	None	-	0	Human	9.0	pIC50	=	9	Binding	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	3842	2403	0	None	-	0	Human	4.5	pIC50	>	4.5	Binding	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3842	2403	0	None	-	0	Human	6.0	pIC50	>	6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	129887154	576	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	576	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	576	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	576	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	576	0	None	-	1	Human	9.2	pKd	=	9.2	Binding	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	53314964	214570	0	125I-VIP	-1	3	Rat	9.4	pKi	=	9.4	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	214570	0	125I-VIP	-5	3	Human	8.7	pKi	=	8.7	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	214570	0	125I-VIP	-1	3	Rat	8.7	pKi	=	8.7	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	214570	0	125I-VIP	-5	3	Human	8.3	pKi	=	8.3	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	214570	0	125I-VIP	-5	3	Human	8.2	pKi	=	8.2	Binding	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	1152	3932	13	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16129679	3932	13	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	53395115	3932	13	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	91898389	3932	13	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	CHEMBL1981592	3932	13	None	-5	4	Human	7.8	pKi	=	7.8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	2276	3293	0	None	316	2	Human	8.0	pKi	=	8	Binding	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	2278	325	0	None	-316	2	Human	5.6	pKi	=	5.6	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3932	13	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	16129679	3932	13	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	53395115	3932	13	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	91898389	3932	13	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	CHEMBL1981592	3932	13	None	-5	4	Human	8.8	pKi	=	8.8	Binding	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3932	13	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	16129679	3932	13	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	53395115	3932	13	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	91898389	3932	13	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	CHEMBL1981592	3932	13	None	-5	4	Human	8.7	pKi	=	8.7	Binding	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823

Join us

Cite us

Main reference

Ligand source activities (1 row/activity)